Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia

This study has been completed.
Sponsor:
Collaborators:
Cell Pathways
OSI Pharmaceuticals
Information provided by (Responsible Party):
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT00036257
First received: May 8, 2002
Last updated: October 14, 2011
Last verified: October 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2003
  Estimated Primary Completion Date: No date given